Grace Therapeutics reported earnings of -$ 0.11 per GRCE share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.15 |
| Earnings Per Share (Surprise) | -$ 0.11 (+$ 0.04) |
| Last Year's EPS | -$ 0.08 |
| EPS YoY Change |
Out of the last 70 earnings reporting periods, Grace Therapeutics beat analysts’ expectations 9 times and fell short of expectations 6 time(s). Grace Therapeutics reported earnings per share of -$ 0.11 in the last report surpassing an estimated EPS of -$ 0.15 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.15 | -$ 0.11 | -$ 0.08 | |
| Aug 13, 2026 | -$ 0.13 | -$ 0.91 | -$ 0.21 | |
| Jun 18, 2026 | -$ 0.24 | -$ 0.07 | $ 0.10 | |
| Feb 12, 2026 | -$ 0.09 | -$ 0.14 | -$ 0.26 | |
| Nov 13, 2025 | -$ 0.12 | -$ 0.08 | -$ 0.33 | |
| Aug 12, 2025 | -$ 0.22 | -$ 0.21 | -$ 0.24 | |
| Jun 23, 2025 | -$ 0.20 | $ 0.10 | -$ 0.17 | |
| Feb 13, 2025 | -$ 0.24 | -$ 0.26 | -$ 0.21 | |
| Nov 13, 2024 | -$ 0.33 | -$ 0.33 | -$ 0.43 | |
| Aug 9, 2024 | -$ 0.27 | -$ 0.24 | -$ 0.54 | |
| Jun 21, 2024 | -$ 0.35 | -$ 0.17 | -$ 3.90 | |
| Feb 12, 2024 | -$ 0.23 | -$ 0.21 | -$ 0.54 | |
| Nov 13, 2023 | -$ 0.26 | -$ 0.43 | -$ 0.66 | |
| Aug 11, 2023 | -$ 0.28 | -$ 0.54 | -$ 0.79 | |
| Jun 23, 2023 | -$ 0.84 | -$ 3.90 | -$ 0.72 | |
| Feb 14, 2023 | -$ 0.74 | -$ 0.54 | -$ 0.65 | |
| Nov 14, 2022 | - | -$ 0.66 | $ 0.23 | |
| Aug 11, 2022 | - | -$ 0.79 | -$ 1.10 | |
| Jun 21, 2022 | - | -$ 0.72 | -$ 3.91 | |
| Feb 14, 2022 | - | -$ 0.65 | -$ 2.52 |
Grace Therapeutics’s stock was trading at $ 1.86 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, GRCE’s price decreased to $ 1.81 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.11 | $ 1.86 | $ 1.81 | |
| Aug 13, 2026 | -$ 0.91 | $ 2.10 | $ 2.16 | |
| Jun 18, 2026 | -$ 0.07 | $ 2.22 | $ 2.26 | |
| Feb 12, 2026 | -$ 0.14 | $ 3.59 | $ 3.61 | |
| Nov 13, 2025 | -$ 0.08 | $ 3.03 | $ 3.06 | |
| Aug 12, 2025 | -$ 0.21 | $ 3.10 | $ 3.28 | |
| Jun 23, 2025 | $ 0.10 | $ 3.00 | $ 3.00 | |
| Feb 13, 2025 | -$ 0.26 | $ 3.48 | $ 3.45 | |
| Nov 13, 2024 | -$ 0.33 | $ 3.19 | $ 3.31 |
Grace Therapeutics released its most recent earnings reports in November 2026, August 2026, June 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Grace Therapeutics beat analysts’ expectations during the last earnings period by
